Mesoblast (MEOBF) EBITDA Margin Growth (3y) (2017 - 2023)
Powered by 
Analysis
Mesoblast (MEOBF) EBITDA Margin Growth (3y) (2017 - 2023) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | - |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | -101,581.00 |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | 4.62 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | -20,903.00 |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | 179,305.00 |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | -2.53 Mn |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 123,643.00 |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | 5,442.00 |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 1,354.00 |
| 10 | Mesoblast | 246.02 Mn | 143.11 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2023 | -102,378.00 |
| Dec 31, 2022 | -31,416.00 |
| Sep 30, 2022 | -136,244.00 |
| Jun 30, 2022 | 923,154.00 |
| Mar 31, 2022 | 114,137.00 |
| Dec 31, 2021 | 71,372.00 |
| Sep 30, 2021 | -53,580.00 |
| Jun 30, 2021 | 996,396.00 |
| Mar 31, 2021 | 77,692.00 |
| Dec 31, 2020 | -111,859.00 |
| Sep 30, 2020 | -129,144.00 |
| Mar 31, 2020 | 137,459.00 |
| Dec 31, 2019 | 319,907.00 |
| Sep 30, 2019 | 610,078.00 |
| Jun 30, 2019 | -125,306.00 |
| Mar 31, 2019 | -182,730.00 |
| Dec 31, 2018 | -99,522.00 |
| Sep 30, 2018 | 10,415.00 |
| Jun 30, 2018 | -59,490.00 |
| Mar 31, 2018 | -175,916.00 |